SNY - Sanofi ADR

SNY - Sanofi ADR

https://www.sanofi.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Sanofi: Information concerning the total number of voting rights and shares - August 2025

GlobeNewswire • 2 days, 23 hours ago • score: 0.33

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce ( the French Commercial Code ) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers ( Regulation of the French stock market ...

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Zacks Commentary • 3 days, 23 hours ago • score: 0.14

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Benzinga • 4 days, 10 hours ago • score: 0.13

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degeneration

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

GlobeNewswire • 4 days, 10 hours ago • score: 0.12

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

52W High

$57.57

52W Low

$43.86

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.44

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

15.50

Forward P/E (<15 better)

9.28

EV/EBITDA (<8 favorable)

8.24

EV/Revenue (<3 favorable)

2.27

P/S (TTM) (<3 favorable)

2.48

P/B (<3 favorable)

1.39

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

10.28%

Shares Outstanding

2,438,960,000

Float

1,096,299,000

Dividend Yield (2–6% sweet spot)

0.09%

Ex‑Dividend Date

2025-05-09

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

45,738,000,000

Gross Profit (TTM)

32,621,001,000

EPS (TTM)

3.00

Profit Margin (>10% good)

0.20%

Operating Margin (TTM) (higher better)

0.18%

ROE (TTM) (>15% strong)

0.09%

EPS YoY (Quarterly) (>10% good)

2.67

Revenue YoY (Quarterly) (>8% good)

-0.06

Momentum

Bearish momentum

Value

-0.6573

Previous

-0.6114

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025